Sun Pharma: Revenues in line as strength in India offsets US drag, margins softer

Research evidence excerpt

Sun Pharma: Revenues in line as strength in India offsets US drag, margins softer

Bansi Desai, CFA AC Asia Pacific Equity Research

(91 22) 6157 3581 03 August 2026 J P M O R G A N

bansi.desai@jpmorgan.com

this research. Where more than one legal entity is listed under an analyst’s name, the first legal entity is responsible for the production unless

stated otherwise. Research Analysts from various J.P. Morgan affiliates may have contributed to the production of this material but may not be

licensed to carry out regulated activities in your jurisdiction (and do not hold themselves out as being able to do so). Unless otherwise stated

below in the legal entity disclosures, this material has been distributed by the legal entity responsible for production, or where more than one

legal entity is listed under the analyst’s name, the first legal entity will be responsible for distribution. If you have any queries, please contact the

relevant Research Analyst in your jurisdiction or the entity in your jurisdiction that has distributed this research material.

Legal Entities Disclosures and Country-/Region-Specific Disclosures:

Argentina: JPMorgan Chase Bank N.A Sucursal Buenos Aires is regulated by Banco Central de la República Argentina (“BCRA”- Central

Bank of Argentina) and Comisión Nacional de Valores (“CNV”- Argentinian Securities Commission - ALYC y AN Integral N°51).

Australia: J.P. Morgan Securities Australia Limited (“JPMSAL”) (ABN 61 003 245 234/AFS Licence No: 238066) is regulated by the

Australian Securities and Investments Commission and is a Market Participant of ASX Limited, a Clearing and Settlement Participant of ASX

Clear Pty Limited and a Clearing Participant of ASX Clear (Futures) Pty Limited. This material is issued and distributed in Australia by or on